ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

Standards of Care and Future Directions in FL

Martin Dreyling

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

EZH2 Inhibition in FL: Overview and Analysis of the SYMPHONY-1 Trial

Northwestern Medicine Oncology and Hematology

L. Gordon

CAR T-Cell Therapy in Autoimmune Disorders

Vanderbilt University Medical Center (VUMC)

O. Oluwole

The Next Frontier of Targeted Therapy in Lymphoma

UChicago Medicine

K. Maddocks

ESMO 2024 Summary: Primary CNS Lymphoma - Updated ESMO and EHA Guide…

2024 ESMO Annual Meeting Insights Hub

A. Ferreri

UChicago Medicine Best of ASCO® 2024: HL, DLBCL, MCL

UChicago Medicine Annual Practice Updates in Hematology and Oncology

A. Rojek

Key Lymphoma Updates From ASH

Memorial Sloan Kettering Cancer Center

P. Torka

Practice-Changing Abstracts in NHL and HL From ASH 2023

UChicago Medicine

S. Smith

CLL and MCL: Experts Discuss the Use of Pirtobrutinib

MyCancerHaven

R. Vij, G. Shouse

MZL: Current Management and Emerging Therapeutics

University of Miami Sylvester Comprehensive Cancer Center

I. Lossos

Practical Updates on Advances in CLL and MCL

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

E. Chong

Standards of Care and Future Directions in MCL

Martin Dreyling

Summary and Practice Impacts of Recent Updates in B-Cell Lymphomas

University of Colorado Division of Hematology

M. Kamdar

DLBCL: Principles of Diagnosis, Prognosis and Staging

University of Colorado Division of Hematology

C. Pearson

When Not to Watch and Wait: Emerging Strategies in the Treatment of …

Indy Hematology Review

M. Williams

EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctu…

Insights from 2024 EHA Annual Meeting

M. Salamoon